NO20090593L - Modulatorer av farmakokinetikkegenskaper til terapeutika - Google Patents

Modulatorer av farmakokinetikkegenskaper til terapeutika

Info

Publication number
NO20090593L
NO20090593L NO20090593A NO20090593A NO20090593L NO 20090593 L NO20090593 L NO 20090593L NO 20090593 A NO20090593 A NO 20090593A NO 20090593 A NO20090593 A NO 20090593A NO 20090593 L NO20090593 L NO 20090593L
Authority
NO
Norway
Prior art keywords
therapeutics
modulators
pharmacokinetic properties
compounds
administration
Prior art date
Application number
NO20090593A
Other languages
English (en)
Other versions
NO343776B1 (no
Inventor
Manoj C Desai
Allen Yu Hong
Hongtao Liu
Lianhong Xu
Randall W Vivian
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090593(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of NO20090593L publication Critical patent/NO20090593L/no
Publication of NO343776B1 publication Critical patent/NO343776B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C07C209/78—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton from carbonyl compounds, e.g. from formaldehyde, and amines having amino groups bound to carbon atoms of six-membered aromatic rings, with formation of methylene-diarylamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Physics & Mathematics (AREA)

Abstract

eller farmasøytisk akseptabelt salt, solvat og/eller ester derav, preparater som inneholder slike forbindelser, terapeutiske fremgangsmåter som inkluderer administreringen av slike forbindelser, og terapeutiske fremgangsmåter som inkluderer administreringen av slike forbindelser sammen med minst ett terapeutisk tilleggsmiddel.
NO20090593A 2006-07-07 2009-02-06 Forbindelse som modulerer farmakokinetikkegenskaper til terapeutika, dens anvendelse i terapi og farmasøytisk sammensetning derav. NO343776B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81931506P 2006-07-07 2006-07-07
US83237106P 2006-07-21 2006-07-21
US90322807P 2007-02-23 2007-02-23
PCT/US2007/015604 WO2008010921A2 (en) 2006-07-07 2007-07-06 Modulators of pharmacokinetic properties of therapeutics

Publications (2)

Publication Number Publication Date
NO20090593L true NO20090593L (no) 2009-04-07
NO343776B1 NO343776B1 (no) 2019-06-03

Family

ID=38729072

Family Applications (4)

Application Number Title Priority Date Filing Date
NO20090593A NO343776B1 (no) 2006-07-07 2009-02-06 Forbindelse som modulerer farmakokinetikkegenskaper til terapeutika, dens anvendelse i terapi og farmasøytisk sammensetning derav.
NO20190528A NO345343B1 (no) 2006-07-07 2019-04-23 Forbindelse eller et farmasøytisk akseptabelt salt, solvat og/eller ester derav, dens anvendelse i terapi, og dens anvendelse for forbedring av farmakokinetikken til et legemiddel som metaboliseres av cytokrom P450-monooksygenase, for økning av blodplasmanivået av et legemiddel som metaboliseres av cytokrom P450-monooksygenase, for inhibering av cytokrom P450-monooksygenase, for behandling av en HIV-infeksjon eller behandling av en HCV-infeksjon hos en pasient; en farmasøytisk sammensetning derav
NO2019027C NO2019027I1 (no) 2006-07-07 2019-07-04 kobicistat eller et farmasøytisk akseptabelt salt derav
NO2019031C NO2019031I1 (no) 2006-07-07 2019-07-19 Stribild (elvitegravir/cobicistat/emtricitabine/TDF - Forlenget SPC

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO20190528A NO345343B1 (no) 2006-07-07 2019-04-23 Forbindelse eller et farmasøytisk akseptabelt salt, solvat og/eller ester derav, dens anvendelse i terapi, og dens anvendelse for forbedring av farmakokinetikken til et legemiddel som metaboliseres av cytokrom P450-monooksygenase, for økning av blodplasmanivået av et legemiddel som metaboliseres av cytokrom P450-monooksygenase, for inhibering av cytokrom P450-monooksygenase, for behandling av en HIV-infeksjon eller behandling av en HCV-infeksjon hos en pasient; en farmasøytisk sammensetning derav
NO2019027C NO2019027I1 (no) 2006-07-07 2019-07-04 kobicistat eller et farmasøytisk akseptabelt salt derav
NO2019031C NO2019031I1 (no) 2006-07-07 2019-07-19 Stribild (elvitegravir/cobicistat/emtricitabine/TDF - Forlenget SPC

Country Status (34)

Country Link
US (11) US7939553B2 (no)
EP (4) EP2049506B2 (no)
JP (2) JP4881433B2 (no)
KR (3) KR101636221B1 (no)
CN (2) CN101490023B (no)
AP (1) AP2985A (no)
AR (1) AR061838A1 (no)
AU (1) AU2007275860C1 (no)
BR (1) BRPI0714055B8 (no)
CA (1) CA2653374A1 (no)
CY (2) CY1116688T1 (no)
DK (1) DK2049506T4 (no)
EA (2) EA020489B1 (no)
ES (3) ES2611308T3 (no)
FI (2) FIC20150052I1 (no)
FR (1) FR15C0078I2 (no)
HK (2) HK1126485A1 (no)
HR (2) HRP20090077B1 (no)
HU (1) HUE025565T4 (no)
IL (2) IL195488A (no)
LT (1) LTC2049506I2 (no)
LU (1) LU92864I2 (no)
ME (1) ME02258B (no)
MX (1) MX2009000234A (no)
NL (1) NL300780I1 (no)
NO (4) NO343776B1 (no)
NZ (1) NZ573060A (no)
PL (1) PL2049506T5 (no)
PT (2) PT2487165T (no)
RS (1) RS54237B2 (no)
SG (1) SG183007A1 (no)
SI (1) SI2049506T2 (no)
TW (2) TWI411613B (no)
WO (1) WO2008010921A2 (no)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7786153B2 (en) 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
EP2049506B2 (en) 2006-07-07 2024-05-08 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
EP2465856A3 (en) * 2006-08-31 2012-12-12 Abbott Laboratories Cytochrome P450 oxidase inhibitors and uses thereof
ME02631B (me) 2007-02-23 2017-06-20 Gilead Sciences Inc Modulatori farmakokinetičkih svojstava lijekova
AU2013204817B2 (en) * 2007-02-23 2015-05-07 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
PT2487163T (pt) * 2007-02-23 2016-11-21 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
AU2015204378B2 (en) * 2007-02-23 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
AU2008270630B2 (en) * 2007-06-29 2014-01-16 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
EA200971096A1 (ru) * 2007-06-29 2010-08-30 Джилид Сайэнс, Инк. Терапевтические композиции и их применение
AR067412A1 (es) 2007-07-06 2009-10-07 Gilead Sciences Inc Moduladores de propiedades farmaceuticas de productos terapeuticos
WO2009067225A2 (en) * 2007-11-20 2009-05-28 Concert Pharmaceuticals, Inc. Boceprevir derivatives for the treatment of hcv infections
PT2231628E (pt) 2008-01-04 2015-12-29 Gilead Sciences Inc Inibidores de citocromo p450
EP3085377A1 (en) 2008-01-25 2016-10-26 Chimerix, Inc. Methods of treating viral infections
MX2010011963A (es) * 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
AU2010210598B2 (en) 2009-02-06 2015-03-05 Gilead Sciences, Inc. Tablets for combination therapy
UA108738C2 (uk) * 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
UY33311A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidatos de nucleosidos
EP2418196A1 (en) * 2010-07-29 2012-02-15 IMTM GmbH Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
WO2012045007A1 (en) 2010-10-01 2012-04-05 Gilead Sciences, Inc. Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US20130280212A1 (en) * 2010-12-21 2013-10-24 Gilead Sciences, Inc Inhibitors of cytochrome p450
US20140187771A1 (en) * 2011-05-02 2014-07-03 Gilead Sciences, Inc. Amorphous solid salts
ES2651212T3 (es) 2011-07-07 2018-01-25 Janssen Sciences Ireland Uc Formulaciones combinadas de darunavir
UY34262A (es) 2011-08-16 2013-04-05 Gilead Sciences Inc Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos
SI2709613T2 (sl) 2011-09-16 2020-12-31 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Postopki za zdravljenje HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CA2856722C (en) 2011-11-30 2022-11-22 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
US20150004239A1 (en) 2012-01-12 2015-01-01 Gilead Sciences, Inc. Pharmaceutical compositions and methods for their preparation
JP2015510509A (ja) 2012-02-03 2015-04-09 ギリアード サイエンシーズ， インコーポレイテッド 医薬品を調製するための方法および中間体
WO2013130766A1 (en) 2012-03-01 2013-09-06 Gilead Sciences, Inc. Spray dried formulations
CN104540813A (zh) * 2012-06-27 2015-04-22 默沙东公司 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法
WO2014000178A1 (en) * 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CN103694196A (zh) * 2012-09-27 2014-04-02 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
US20160200716A1 (en) * 2012-12-26 2016-07-14 Assia Chemical Industries Ltd. Cobicistat dichlohydrate salt
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2014194519A1 (en) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug
CN104370777A (zh) * 2013-08-13 2015-02-25 上海迪赛诺化学制药有限公司 合成(2r,5r)-1,6-二苯基己烷-2,5-二胺及其盐的中间体及所述中间体的制备方法和应用
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
WO2015070366A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2015070367A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CA2931971A1 (en) 2013-11-29 2015-06-04 Mylan Laboratories Ltd. Amorphous cobicistat solid dispersion
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
CN105198829B (zh) * 2015-08-15 2017-10-31 浙江永宁药业股份有限公司 一种可比司他中间体的制备方法及其中间体和用途
TW201728582A (zh) 2016-01-28 2017-08-16 基利科學股份有限公司 結晶型
US10653681B2 (en) 2016-03-16 2020-05-19 Recurium Ip Holdings, Llc Analgesic compounds
CN105884760B (zh) * 2016-06-13 2019-01-04 厦门市蔚嘉化学科技有限公司 一种可比司他中间体的制备方法
CN107674039A (zh) * 2016-08-01 2018-02-09 上海朴颐化学科技有限公司 一种可比西他中间体的制备方法
US20180036289A1 (en) * 2016-08-04 2018-02-08 Gilead Sciences, Inc. Cobicistat for use in cancer treatments
EP3518935A1 (en) 2016-09-27 2019-08-07 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
WO2018115319A2 (en) 2016-12-23 2018-06-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases
WO2019027920A1 (en) 2017-08-01 2019-02-07 Gilead Sciences, Inc. CRYSTALLINE FORMS OF ETHYL ((S) - (((((2R, 5R) -5- (6-AMINO-9H-PURIN-9-YL) -4-FLUORO-2,5-DIHYDROFURAN-2-YL) OXY ) METHYL) (PHENOXY) PHOSPHORYL) -L-ALANINATE (GS-9131) FOR THE TREATMENT OF VIRAL INFECTIONS
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
KR20210095618A (ko) * 2018-11-26 2021-08-02 미쯔비시 가스 케미칼 컴파니, 인코포레이티드 수계 에폭시 수지 조성물 및 그의 경화물
CN111329858B (zh) * 2018-12-18 2022-09-20 深圳先进技术研究院 一种小分子抑制剂在抑制病毒沉默抑制蛋白中的应用
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4244396A1 (en) 2020-11-11 2023-09-20 Gilead Sciences, Inc. Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
IL312718A (en) 2021-12-03 2024-07-01 Gilead Sciences Inc Therapeutic compounds for HIV infection
CN118355020A (zh) 2021-12-03 2024-07-16 吉利德科学公司 Hiv病毒感染的治疗性化合物
TW202342447A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TW202402280A (zh) 2022-07-01 2024-01-16 美商基利科學股份有限公司 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
US20240083984A1 (en) 2022-08-26 2024-03-14 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3354866A (en) * 1966-04-25 1967-11-28 Frank D Karkoska Coating apparatus including means to rotate and translate a rod-substrate
US3882114A (en) * 1967-10-26 1975-05-06 Oreal N-(morpholinomethyl carbamyl) cysteamine and glycine
GB1339764A (en) * 1971-03-29 1973-12-05 Ici Ltd Pyridine derivatives
US3957774A (en) * 1972-04-17 1976-05-18 L'oreal N-morpholinomethyl-n-'-substituted ethyl and propylureas
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
HU186777B (en) 1981-07-09 1985-09-30 Magyar Tudomanyos Akademia Process for producing complex-forming agents of crown-ether base and ionoselective membranelektrodes containing them
DE3478684D1 (en) * 1983-11-02 1989-07-20 Magyar Tudomanyos Akademia Crown ether derivatives
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5362912A (en) * 1989-05-23 1994-11-08 Abbott Laboratories Process for the preparation of a substituted diaminodiol
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
EP0428849A3 (en) 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
IE20010533A1 (en) 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
JPH06127981A (ja) 1992-03-03 1994-05-10 Fuainiteii Kk 複合複層ガラス及びそれを使用した窓
US5556418A (en) * 1993-07-06 1996-09-17 Pappas; Panagiotis T. Method and apparatus for pulsed magnetic induction
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
DE69332616T2 (de) 1992-12-29 2003-11-06 Abbott Laboratories, Abbott Park Hemmer der retroviralen Protease
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5763464A (en) * 1995-11-22 1998-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
AU2010299A (en) * 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
FR2773994B1 (fr) 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
ATE332132T1 (de) * 1999-06-04 2006-07-15 Abbott Lab Verbesserte arzneizubereitungen enthaltend ritonavir
DK1222192T3 (da) 1999-10-06 2008-10-20 Tibotec Pharm Ltd Hexahydrofuro-2,3-b furan-3-yl-N-3-(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino-1-benzyl-2-hydroxypropyl-carbamat som retroviral proteaseinhibitor
US6252336B1 (en) 1999-11-08 2001-06-26 Cts Corporation Combined piezoelectric silent alarm/battery charger
US6448245B1 (en) * 2000-05-04 2002-09-10 The United States Of America As Represented By The Department Of Health And Human Services Methods of and compounds for inhibiting calpains
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7285566B2 (en) 2002-01-07 2007-10-23 Erickson John W Resistance-repellent retroviral protease inhibitors
US7279487B2 (en) 2002-01-17 2007-10-09 Merck & Co., Inc. Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
US7205413B2 (en) * 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
EP1564210B9 (en) 2002-11-20 2010-03-31 Japan Tobacco Inc. 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
JP2004184681A (ja) * 2002-12-03 2004-07-02 Konica Minolta Holdings Inc 熱現像感光材料
KR20090053867A (ko) 2003-01-14 2009-05-27 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
US7737608B2 (en) 2003-07-30 2010-06-15 The Boeing Company Enhanced amplitude piezoelectric motor apparatus and method
JP2005091988A (ja) * 2003-09-19 2005-04-07 Konica Minolta Medical & Graphic Inc 熱現像感光材料及び画像形成方法
PL1677827T3 (pl) * 2003-10-27 2009-06-30 Vertex Pharma Połączenia do leczenia HCV
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
JP2006003701A (ja) * 2004-06-18 2006-01-05 Konica Minolta Medical & Graphic Inc 熱現像感光材料および画像形成方法
WO2006014282A2 (en) * 2004-07-06 2006-02-09 Abbott Laboratories Prodrugs of hiv protease inhibitors
US7786153B2 (en) * 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
EP2049506B2 (en) * 2006-07-07 2024-05-08 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
EP2465856A3 (en) 2006-08-31 2012-12-12 Abbott Laboratories Cytochrome P450 oxidase inhibitors and uses thereof
PT2487163T (pt) * 2007-02-23 2016-11-21 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
AU2008270630B2 (en) 2007-06-29 2014-01-16 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
EA200971096A1 (ru) 2007-06-29 2010-08-30 Джилид Сайэнс, Инк. Терапевтические композиции и их применение
AR067412A1 (es) * 2007-07-06 2009-10-07 Gilead Sciences Inc Moduladores de propiedades farmaceuticas de productos terapeuticos
KR20160012252A (ko) 2007-12-27 2016-02-02 백스터 인터내셔널 인코포레이티드 생리학적으로 수용가능한 중합체 분자를 특이적으로 검출하기 위한 방법 및 조성물
MX2010011963A (es) 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
AU2010210598B2 (en) 2009-02-06 2015-03-05 Gilead Sciences, Inc. Tablets for combination therapy

Also Published As

Publication number Publication date
US7939553B2 (en) 2011-05-10
TW200811167A (en) 2008-03-01
PT2487165T (pt) 2016-11-18
RS54237B9 (sr) 2019-07-31
US20150011775A1 (en) 2015-01-08
HUE025565T4 (en) 2017-01-30
EA201270738A1 (ru) 2013-07-30
CY1116688T1 (el) 2016-06-22
TWI496778B (zh) 2015-08-21
ES2611308T3 (es) 2017-05-08
US9139541B2 (en) 2015-09-22
FIC20150052I1 (fi) 2015-11-06
HK1126485A1 (en) 2009-09-04
IL232320A0 (en) 2014-06-30
HRP20150744T1 (en) 2015-10-09
HUE025565T2 (en) 2016-03-29
CA2653374A1 (en) 2008-01-24
EA025845B1 (ru) 2017-02-28
HRP20090077A2 (en) 2009-06-30
WO2008010921A2 (en) 2008-01-24
NZ573060A (en) 2012-02-24
LTC2049506I2 (lt) 2019-05-10
EP2049506B2 (en) 2024-05-08
LU92864I2 (fr) 2016-01-06
US20140105859A1 (en) 2014-04-17
US20160067360A1 (en) 2016-03-10
NL300780I2 (no) 2016-03-15
AU2007275860A1 (en) 2008-01-24
FR15C0078I2 (fr) 2016-04-22
BRPI0714055B8 (pt) 2021-05-25
ES2546378T9 (es) 2016-01-26
US20080108617A1 (en) 2008-05-08
CY2015046I1 (el) 2016-06-22
WO2008010921A3 (en) 2008-07-10
MX2009000234A (es) 2009-01-23
JP2012051933A (ja) 2012-03-15
CY2015046I2 (el) 2016-06-22
DK2049506T5 (en) 2016-02-15
ES2546378T3 (es) 2015-09-23
JP4881433B2 (ja) 2012-02-22
NO343776B1 (no) 2019-06-03
CN101490023A (zh) 2009-07-22
LTPA2015040I1 (lt) 2015-12-28
EA020489B1 (ru) 2014-11-28
EP2487165B1 (en) 2016-09-14
DK2049506T3 (en) 2015-09-14
TWI411613B (zh) 2013-10-11
NO20190528A1 (no) 2009-04-07
NO2019027I1 (no) 2019-07-04
KR101477822B1 (ko) 2015-01-02
RS54237B1 (en) 2015-12-31
US8067449B2 (en) 2011-11-29
EP2487165A1 (en) 2012-08-15
FR15C0078I1 (no) 2016-01-08
DK2049506T4 (da) 2024-06-10
RS54237B2 (sr) 2024-08-30
FI2049506T4 (fi) 2024-06-12
JP2009542696A (ja) 2009-12-03
NO345343B1 (no) 2020-12-21
CN103275033B (zh) 2015-04-29
HRP20150744T2 (hr) 2016-02-26
AP2008004720A0 (en) 2008-12-31
HRP20090077B1 (hr) 2016-04-08
US20130123311A1 (en) 2013-05-16
EP3112355A1 (en) 2017-01-04
EP2049506A2 (en) 2009-04-22
SG183007A1 (en) 2012-08-30
TW201412733A (zh) 2014-04-01
US20150225448A1 (en) 2015-08-13
SI2049506T2 (sl) 2024-07-31
PL2049506T5 (pl) 2024-09-09
SI2049506T1 (sl) 2015-08-31
CN101490023B (zh) 2013-05-29
KR20140004808A (ko) 2014-01-13
PT2049506E (pt) 2015-10-09
AU2007275860C1 (en) 2014-06-12
US8383655B2 (en) 2013-02-26
KR20150042869A (ko) 2015-04-21
US20110212964A1 (en) 2011-09-01
CN103275033A (zh) 2013-09-04
US20160303088A1 (en) 2016-10-20
US20180221348A1 (en) 2018-08-09
NO2019031I1 (no) 2019-07-19
IL195488A0 (en) 2009-09-01
PL2049506T3 (pl) 2015-11-30
AR061838A1 (es) 2008-09-24
ES2796275T3 (es) 2020-11-26
EP2049506B9 (en) 2016-01-13
AU2007275860B2 (en) 2013-11-14
IL195488A (en) 2017-04-30
BRPI0714055A2 (pt) 2012-12-18
KR20090028821A (ko) 2009-03-19
US20090291952A1 (en) 2009-11-26
HK1232217A1 (zh) 2018-01-05
NL300780I1 (no) 2016-03-15
EA200900155A1 (ru) 2009-06-30
EP3696171A1 (en) 2020-08-19
AP2985A (en) 2014-09-30
US20170143680A1 (en) 2017-05-25
EP3112355B1 (en) 2020-04-29
EP2049506B1 (en) 2015-06-17
ME02258B (me) 2015-12-31
BRPI0714055B1 (pt) 2019-05-21
KR101636221B1 (ko) 2016-07-04

Similar Documents

Publication Publication Date Title
NO20090593L (no) Modulatorer av farmakokinetikkegenskaper til terapeutika
CY1122761T1 (el) Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
NO2023022I1 (no) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
NO20090835L (no) Nye HIV-reverstranskriptaseinhibitorer
CY1120435T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν κρυσταλλικες μορφες του μονοενυδρου υδροχλωρικου (r)-7-χλωρο-ν-(κινουκλιδινο-3-υλο) βενζο(β)θειοφαινο-2-καρβοξαμιδιου
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
PT2421879E (pt) Novos 7-deazapurina nucleósidos para utilizações terapêuticas
NO20090596L (no) Antivirale fosfinatforbindelser
MX2009003038A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
PT2038290E (pt) Moduladores de receptor do tipo toll 7
TW200613243A (en) Novel compounds
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
MX2007012212A (es) 1h-pirazol 4-carboxilamidas, su preparacion y su uso como 11-beta-hidroxiesteroide deshidrogenasa.
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
RS20090036A (en) Pyrazole derivatives as cytochrom p450 inhibitors
MX2010003923A (es) Formulacion farmaceutica de valsartan.
AU2009331669A8 (en) Dihydropyridone amides as P2X7 modulators
AR063550A2 (es) Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y eltratamiento de la displidemias y de las enefermedades asociadas a las dislipidemias y/o a la obesidad
EA201070689A1 (ru) Композиция для личного ухода
WO2008004100A9 (en) Therapeutic compounds
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions
WO2008011539A3 (en) Anesthetic compounds

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: ELVITEGRAVIR/KOBICISTAT/EMTRICIT ABINE/TENOFOVIRDISOPROKSIL; REG. NO/DATE: EU/1/12/830/001-002 20130701

Spc suppl protection certif: 2019027

Filing date: 20190704

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: STRIBILD; REG. NO/DATE: EU/1/12/830/001-002 20130701

Spc suppl protection certif: 2019031

Filing date: 20190719

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: KOBICISTAT ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV; REG. NO/DATE: EU/1/12/830/001-002 20130701

Spc suppl protection certif: 2019027

Filing date: 20190704

Extension date: 20280527

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: KOBICISTAT ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV; REG. NO/DATE: EU/1/13/830/001-002 20130701

Spc suppl protection certif: 2019031

Filing date: 20190719

Extension date: 20281127